Life sciences and diagnostics firm Revvity, has chosen Bruntwood SciTech’s Alderley Park as its newest UK hub.
As part of plans for a nationwide expansion, the provider of products and services in translational multi-omics technologies, biomarker identification, imaging, screening, detection and diagnosis, will be joining a thriving community of over 250 innovative drug discovery, biotech, medcomms, diagnostics, AI, digital health and beauty tech businesses at the campus.
The leading science and innovation campus by Bruntwood SciTech - the UK’s largest property platform dedicated to the growth of the innovation economy, is a joint venture between Bruntwood, L&G, and Greater Manchester Pension Fund, and has supported Revvity with providing flexible, highly specialist workspace infrastructure and collaborative facilitation. Offering a supportive, well-connected ecosystem, Alderley Park continues to appeal to businesses at every stage of their growth and fundraising journeys, whether they be start-ups, scaleups or large multinationals.
Revvity’s location to Alderley Park follows it securing a world-leading research collaboration with Genomics England on the Generation Study, in collaboration with NHS England. The groundbreaking research aims to screen up to 100,000 newborns and will help inform decisions on using whole genome sequencing to screen for rare genetic conditions, advancing abilities for early detection.
Revvity selected Alderley Park to help support its work and take advantage of the campus’ world-class specialist workspace infrastructure, amenities and power resilience. Revvity will now utilise almost 6,000 sq ft of custom designed and fitted CL2 open-plan laboratory space within its Mereside hub. It will also be accompanied with a state-of-the-art, latest generation backup generator to ensure security and continuity of research.
Focused on advancing research and diagnostics through technology and partnerships, Revvity will be based alongside leading innovators and technology-focused firms at Alderley Park with opportunities for collaboration with forward-thinking companies such as Medicines Discovery Catapult, CellCentric, Globachem Discovery, global software developers SAP, and companies who are part of the Alderley Park Life Sciences Accelerator and Female Founders Incubator.
Revvity will also continue to strengthen its connectivity to the NHS via Bruntwood SciTech’s joint venture partnership with Manchester University NHS Foundation Trust (MFT) and gain direct access to research, collaborations, sample supplies, and direct introductions to clinicians.
Chris Hughes, managing director, North Europe at Revvity, said: “As our work with Genomics England enters an exciting new chapter, so do we. Our UK expansion is about more than simply establishing a presence, it’s about unlocking new opportunities for collaboration and innovation. With access to world-class laboratory infrastructure and unrivalled connectivity to the NHS collaborators and industry peers, our new Alderley Park base will be central to supporting the delivery of the Generation Study as one of the study’s extraction and sequencing collaborators. The Generation Study will help enable earlier diagnoses and better outcomes for newborns, while supporting our broader mission to push the boundaries of what’s possible in healthcare.”